{"id":27158,"date":"2023-07-11T12:36:41","date_gmt":"2023-07-11T16:36:41","guid":{"rendered":"https:\/\/capital10x.com\/old\/?p=27158"},"modified":"2023-07-11T12:36:41","modified_gmt":"2023-07-11T16:36:41","slug":"capital-10x-interview-series-mindset-pharma-leaders-in-next-gen-psychedelics","status":"publish","type":"post","link":"https:\/\/capital10x.com\/old\/capital-10x-interview-series-mindset-pharma-leaders-in-next-gen-psychedelics\/","title":{"rendered":"Capital 10X Interview Series | Mindset Pharma: Leaders in Next-Gen Psychedelics"},"content":{"rendered":"<h2>Mindset Pharma: Leaders in Next-Gen Psychedelics<\/h2>\n<p>We had the pleasure of sitting down with James Lanthier, CEO of Mindset Pharma (CSE: MSET) (OTCQB: MSSTF).\u00a0 We discussed some very exciting news &#8211; the company was recently approved by the MHRA to fast track their lead candidate MSP-1014 to Phase II clinical trials.\u00a0 James also shared the story of their patents for non-hallucinogenic, non-tryptamine psychedelics and his thoughts on the rapid progress of the psychedelic movement.\u00a0 He also shared Mindset Pharma&#8217;s edge &#8211; the buildout of a diverse library of intellectual property.<\/p>\n<p><a href=\"https:\/\/www.youtube.com\/watch?v=b5ptoY99JEE&amp;t=0s\">0:00<\/a> Fast tracking MSP-1014 to Phase II Clinical Trials<br \/>\n<a href=\"https:\/\/www.youtube.com\/watch?v=b5ptoY99JEE&amp;t=167s\">2:47<\/a> Mindset Pharma\u2019s Edge<br \/>\n<a href=\"https:\/\/www.youtube.com\/watch?v=b5ptoY99JEE&amp;t=275s\">4:35<\/a> Diverse Portfolio of Drugs<br \/>\n<a href=\"https:\/\/www.youtube.com\/watch?v=b5ptoY99JEE&amp;t=391s\">6:31<\/a> Patents for Non-Hallucinogenic, Non-Tryptamine Compounds<br \/>\n<a href=\"https:\/\/www.youtube.com\/watch?v=b5ptoY99JEE&amp;t=546s\">9:06<\/a> The Controversy with Psychedelics without the High<br \/>\n<a href=\"https:\/\/www.youtube.com\/watch?v=b5ptoY99JEE&amp;t=672s\">11:12<\/a> The Rapid Pace of Psychedelics Advancement<\/p>\n<div class=\"youtube-embed\" data-video_id=\"b5ptoY99JEE\"><iframe loading=\"lazy\" title=\"Mindset Pharma: Leaders in Next-Gen Psychedelics\" width=\"696\" height=\"392\" src=\"https:\/\/www.youtube.com\/embed\/b5ptoY99JEE?feature=oembed&#038;enablejsapi=1&#038;enablejsapi=1&#038;origin=https:\/\/capital10x.com\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" allowfullscreen><\/iframe><\/div>\n","protected":false},"excerpt":{"rendered":"<p>We had the pleasure of sitting down with James Lanthier, CEO of Mindset Pharma (CSE: MSET) (OTCQB: MSSTF).\u00a0 We discussed some very exciting news &#8211; the company was recently approved by the MHRA to fast track their lead candidate MSP-1014 to Phase II clinical trials.\u00a0 James also shared the story of their patents for non-hallucinogenic, non-tryptamine psychedelics and his thoughts on the rapid progress of the psychedelic movement.\u00a0 He also shared Mindset Pharma&#8217;s edge &#8211; the buildout of a diverse library of intellectual property.<\/p>\n","protected":false},"author":25,"featured_media":27154,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1112,69],"tags":[1995,1837,1927,1760,1811,1864,1829,1824],"class_list":{"0":"post-27158","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-tech","8":"category-videos","9":"tag-5meo-dmt","10":"tag-dmt","11":"tag-drugs","12":"tag-mindset-pharma","13":"tag-mset","14":"tag-msstf","15":"tag-patents","16":"tag-psychedelics"},"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Capital 10X Interview Series | Mindset Pharma: Leaders in Next-Gen Psychedelics | Capital 10X<\/title>\n<meta name=\"description\" content=\"We had the pleasure of sitting down with James Lanthier, CEO of Mindset Pharma (CSE: MSET) (OTCQB: MSSTF).\u00a0 We discussed some very exciting news - the company was recently approved by the MHRA to fast track their lead candidate MSP-1014 to Phase II clinical trials.\u00a0 James also shared the story of their patents for non-hallucinogenic, non-tryptamine psychedelics and his thoughts on the rapid progress of the psychedelic movement.\u00a0 He also shared Mindset Pharma&#039;s edge - the buildout of a diverse library of intellectual property.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/capital10x.com\/old\/capital-10x-interview-series-mindset-pharma-leaders-in-next-gen-psychedelics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Capital 10X Interview Series | Mindset Pharma: Leaders in Next-Gen Psychedelics | Capital 10X\" \/>\n<meta property=\"og:description\" content=\"We had the pleasure of sitting down with James Lanthier, CEO of Mindset Pharma (CSE: MSET) (OTCQB: MSSTF).\u00a0 We discussed some very exciting news - the company was recently approved by the MHRA to fast track their lead candidate MSP-1014 to Phase II clinical trials.\u00a0 James also shared the story of their patents for non-hallucinogenic, non-tryptamine psychedelics and his thoughts on the rapid progress of the psychedelic movement.\u00a0 He also shared Mindset Pharma&#039;s edge - the buildout of a diverse library of intellectual property.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/capital10x.com\/old\/capital-10x-interview-series-mindset-pharma-leaders-in-next-gen-psychedelics\/\" \/>\n<meta property=\"og:site_name\" content=\"Capital 10X\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/Capital10x\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-11T16:36:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2023\/07\/Mindset-Post.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1069\" \/>\n\t<meta property=\"og:image:height\" content=\"713\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Duane Hope\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@capital10x\" \/>\n<meta name=\"twitter:site\" content=\"@capital10x\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Duane Hope\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/capital10x.com\/old\/capital-10x-interview-series-mindset-pharma-leaders-in-next-gen-psychedelics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/capital10x.com\/old\/capital-10x-interview-series-mindset-pharma-leaders-in-next-gen-psychedelics\/\"},\"author\":{\"name\":\"Duane Hope\",\"@id\":\"https:\/\/capital10x.com\/old\/#\/schema\/person\/75fddffbd75d63e9226bc4c592e9a851\"},\"headline\":\"Capital 10X Interview Series | Mindset Pharma: Leaders in Next-Gen Psychedelics\",\"datePublished\":\"2023-07-11T16:36:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/capital10x.com\/old\/capital-10x-interview-series-mindset-pharma-leaders-in-next-gen-psychedelics\/\"},\"wordCount\":144,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/capital10x.com\/old\/#organization\"},\"image\":{\"@id\":\"https:\/\/capital10x.com\/old\/capital-10x-interview-series-mindset-pharma-leaders-in-next-gen-psychedelics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2023\/07\/Mindset-Post.jpg\",\"keywords\":[\"5MEO-DMT\",\"DMT\",\"drugs\",\"Mindset Pharma\",\"MSET\",\"MSSTF\",\"patents\",\"Psychedelics\"],\"articleSection\":[\"Health &amp; Tech\",\"Videos\"],\"inLanguage\":\"en-CA\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/capital10x.com\/old\/capital-10x-interview-series-mindset-pharma-leaders-in-next-gen-psychedelics\/#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\/\/capital10x.com\/old\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/capital10x.com\/old\/capital-10x-interview-series-mindset-pharma-leaders-in-next-gen-psychedelics\/\",\"url\":\"https:\/\/capital10x.com\/old\/capital-10x-interview-series-mindset-pharma-leaders-in-next-gen-psychedelics\/\",\"name\":\"Capital 10X Interview Series | Mindset Pharma: Leaders in Next-Gen Psychedelics | Capital 10X\",\"isPartOf\":{\"@id\":\"https:\/\/capital10x.com\/old\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/capital10x.com\/old\/capital-10x-interview-series-mindset-pharma-leaders-in-next-gen-psychedelics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/capital10x.com\/old\/capital-10x-interview-series-mindset-pharma-leaders-in-next-gen-psychedelics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2023\/07\/Mindset-Post.jpg\",\"datePublished\":\"2023-07-11T16:36:41+00:00\",\"description\":\"We had the pleasure of sitting down with James Lanthier, CEO of Mindset Pharma (CSE: MSET) (OTCQB: MSSTF).\u00a0 We discussed some very exciting news - the company was recently approved by the MHRA to fast track their lead candidate MSP-1014 to Phase II clinical trials.\u00a0 James also shared the story of their patents for non-hallucinogenic, non-tryptamine psychedelics and his thoughts on the rapid progress of the psychedelic movement.\u00a0 He also shared Mindset Pharma's edge - the buildout of a diverse library of intellectual property.\",\"breadcrumb\":{\"@id\":\"https:\/\/capital10x.com\/old\/capital-10x-interview-series-mindset-pharma-leaders-in-next-gen-psychedelics\/#breadcrumb\"},\"inLanguage\":\"en-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/capital10x.com\/old\/capital-10x-interview-series-mindset-pharma-leaders-in-next-gen-psychedelics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-CA\",\"@id\":\"https:\/\/capital10x.com\/old\/capital-10x-interview-series-mindset-pharma-leaders-in-next-gen-psychedelics\/#primaryimage\",\"url\":\"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2023\/07\/Mindset-Post.jpg\",\"contentUrl\":\"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2023\/07\/Mindset-Post.jpg\",\"width\":1069,\"height\":713},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/capital10x.com\/old\/capital-10x-interview-series-mindset-pharma-leaders-in-next-gen-psychedelics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/capital10x.com\/old\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Videos\",\"item\":\"https:\/\/capital10x.com\/old\/videos\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Capital 10X Interview Series | Mindset Pharma: Leaders in Next-Gen Psychedelics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/capital10x.com\/old\/#website\",\"url\":\"https:\/\/capital10x.com\/old\/\",\"name\":\"Capital 10X\",\"description\":\"Identifying 10X Investment Opportunities\",\"publisher\":{\"@id\":\"https:\/\/capital10x.com\/old\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/capital10x.com\/old\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/capital10x.com\/old\/#organization\",\"name\":\"Capital 10X\",\"url\":\"https:\/\/capital10x.com\/old\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-CA\",\"@id\":\"https:\/\/capital10x.com\/old\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2019\/02\/capital-10X-logo-stacked.png\",\"contentUrl\":\"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2019\/02\/capital-10X-logo-stacked.png\",\"width\":128,\"height\":90,\"caption\":\"Capital 10X\"},\"image\":{\"@id\":\"https:\/\/capital10x.com\/old\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Capital10x\/\",\"https:\/\/x.com\/capital10x\",\"https:\/\/www.instagram.com\/capital10x\",\"https:\/\/www.linkedin.com\/company\/capital10x\/\",\"https:\/\/www.pinterest.com\/capital10x\",\"https:\/\/www.youtube.com\/Capital10X\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/capital10x.com\/old\/#\/schema\/person\/75fddffbd75d63e9226bc4c592e9a851\",\"name\":\"Duane Hope\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-CA\",\"@id\":\"https:\/\/capital10x.com\/old\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1e094aea10a79b65e157d5f0d9968719f11d1fafb952b910a18796349f2e38e9?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1e094aea10a79b65e157d5f0d9968719f11d1fafb952b910a18796349f2e38e9?s=96&d=mm&r=g\",\"caption\":\"Duane Hope\"},\"description\":\"Duane Hope is a Partner at Capital 10X, he brings over 15 years of communications and research experience to the firm. His research and writing has appeared in publications for North American, European and Asian audiences.\",\"sameAs\":[\"http:\/\/capital10x.com\"],\"url\":\"https:\/\/capital10x.com\/old\/author\/duanehope\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Capital 10X Interview Series | Mindset Pharma: Leaders in Next-Gen Psychedelics | Capital 10X","description":"We had the pleasure of sitting down with James Lanthier, CEO of Mindset Pharma (CSE: MSET) (OTCQB: MSSTF).\u00a0 We discussed some very exciting news - the company was recently approved by the MHRA to fast track their lead candidate MSP-1014 to Phase II clinical trials.\u00a0 James also shared the story of their patents for non-hallucinogenic, non-tryptamine psychedelics and his thoughts on the rapid progress of the psychedelic movement.\u00a0 He also shared Mindset Pharma's edge - the buildout of a diverse library of intellectual property.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/capital10x.com\/old\/capital-10x-interview-series-mindset-pharma-leaders-in-next-gen-psychedelics\/","og_locale":"en_US","og_type":"article","og_title":"Capital 10X Interview Series | Mindset Pharma: Leaders in Next-Gen Psychedelics | Capital 10X","og_description":"We had the pleasure of sitting down with James Lanthier, CEO of Mindset Pharma (CSE: MSET) (OTCQB: MSSTF).\u00a0 We discussed some very exciting news - the company was recently approved by the MHRA to fast track their lead candidate MSP-1014 to Phase II clinical trials.\u00a0 James also shared the story of their patents for non-hallucinogenic, non-tryptamine psychedelics and his thoughts on the rapid progress of the psychedelic movement.\u00a0 He also shared Mindset Pharma's edge - the buildout of a diverse library of intellectual property.","og_url":"https:\/\/capital10x.com\/old\/capital-10x-interview-series-mindset-pharma-leaders-in-next-gen-psychedelics\/","og_site_name":"Capital 10X","article_publisher":"https:\/\/www.facebook.com\/Capital10x\/","article_published_time":"2023-07-11T16:36:41+00:00","og_image":[{"width":1069,"height":713,"url":"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2023\/07\/Mindset-Post.jpg","type":"image\/jpeg"}],"author":"Duane Hope","twitter_card":"summary_large_image","twitter_creator":"@capital10x","twitter_site":"@capital10x","twitter_misc":{"Written by":"Duane Hope","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/capital10x.com\/old\/capital-10x-interview-series-mindset-pharma-leaders-in-next-gen-psychedelics\/#article","isPartOf":{"@id":"https:\/\/capital10x.com\/old\/capital-10x-interview-series-mindset-pharma-leaders-in-next-gen-psychedelics\/"},"author":{"name":"Duane Hope","@id":"https:\/\/capital10x.com\/old\/#\/schema\/person\/75fddffbd75d63e9226bc4c592e9a851"},"headline":"Capital 10X Interview Series | Mindset Pharma: Leaders in Next-Gen Psychedelics","datePublished":"2023-07-11T16:36:41+00:00","mainEntityOfPage":{"@id":"https:\/\/capital10x.com\/old\/capital-10x-interview-series-mindset-pharma-leaders-in-next-gen-psychedelics\/"},"wordCount":144,"commentCount":0,"publisher":{"@id":"https:\/\/capital10x.com\/old\/#organization"},"image":{"@id":"https:\/\/capital10x.com\/old\/capital-10x-interview-series-mindset-pharma-leaders-in-next-gen-psychedelics\/#primaryimage"},"thumbnailUrl":"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2023\/07\/Mindset-Post.jpg","keywords":["5MEO-DMT","DMT","drugs","Mindset Pharma","MSET","MSSTF","patents","Psychedelics"],"articleSection":["Health &amp; Tech","Videos"],"inLanguage":"en-CA","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/capital10x.com\/old\/capital-10x-interview-series-mindset-pharma-leaders-in-next-gen-psychedelics\/#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/capital10x.com\/old\/#organization"}},{"@type":"WebPage","@id":"https:\/\/capital10x.com\/old\/capital-10x-interview-series-mindset-pharma-leaders-in-next-gen-psychedelics\/","url":"https:\/\/capital10x.com\/old\/capital-10x-interview-series-mindset-pharma-leaders-in-next-gen-psychedelics\/","name":"Capital 10X Interview Series | Mindset Pharma: Leaders in Next-Gen Psychedelics | Capital 10X","isPartOf":{"@id":"https:\/\/capital10x.com\/old\/#website"},"primaryImageOfPage":{"@id":"https:\/\/capital10x.com\/old\/capital-10x-interview-series-mindset-pharma-leaders-in-next-gen-psychedelics\/#primaryimage"},"image":{"@id":"https:\/\/capital10x.com\/old\/capital-10x-interview-series-mindset-pharma-leaders-in-next-gen-psychedelics\/#primaryimage"},"thumbnailUrl":"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2023\/07\/Mindset-Post.jpg","datePublished":"2023-07-11T16:36:41+00:00","description":"We had the pleasure of sitting down with James Lanthier, CEO of Mindset Pharma (CSE: MSET) (OTCQB: MSSTF).\u00a0 We discussed some very exciting news - the company was recently approved by the MHRA to fast track their lead candidate MSP-1014 to Phase II clinical trials.\u00a0 James also shared the story of their patents for non-hallucinogenic, non-tryptamine psychedelics and his thoughts on the rapid progress of the psychedelic movement.\u00a0 He also shared Mindset Pharma's edge - the buildout of a diverse library of intellectual property.","breadcrumb":{"@id":"https:\/\/capital10x.com\/old\/capital-10x-interview-series-mindset-pharma-leaders-in-next-gen-psychedelics\/#breadcrumb"},"inLanguage":"en-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/capital10x.com\/old\/capital-10x-interview-series-mindset-pharma-leaders-in-next-gen-psychedelics\/"]}]},{"@type":"ImageObject","inLanguage":"en-CA","@id":"https:\/\/capital10x.com\/old\/capital-10x-interview-series-mindset-pharma-leaders-in-next-gen-psychedelics\/#primaryimage","url":"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2023\/07\/Mindset-Post.jpg","contentUrl":"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2023\/07\/Mindset-Post.jpg","width":1069,"height":713},{"@type":"BreadcrumbList","@id":"https:\/\/capital10x.com\/old\/capital-10x-interview-series-mindset-pharma-leaders-in-next-gen-psychedelics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/capital10x.com\/old\/"},{"@type":"ListItem","position":2,"name":"Videos","item":"https:\/\/capital10x.com\/old\/videos\/"},{"@type":"ListItem","position":3,"name":"Capital 10X Interview Series | Mindset Pharma: Leaders in Next-Gen Psychedelics"}]},{"@type":"WebSite","@id":"https:\/\/capital10x.com\/old\/#website","url":"https:\/\/capital10x.com\/old\/","name":"Capital 10X","description":"Identifying 10X Investment Opportunities","publisher":{"@id":"https:\/\/capital10x.com\/old\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/capital10x.com\/old\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-CA"},{"@type":"Organization","@id":"https:\/\/capital10x.com\/old\/#organization","name":"Capital 10X","url":"https:\/\/capital10x.com\/old\/","logo":{"@type":"ImageObject","inLanguage":"en-CA","@id":"https:\/\/capital10x.com\/old\/#\/schema\/logo\/image\/","url":"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2019\/02\/capital-10X-logo-stacked.png","contentUrl":"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2019\/02\/capital-10X-logo-stacked.png","width":128,"height":90,"caption":"Capital 10X"},"image":{"@id":"https:\/\/capital10x.com\/old\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Capital10x\/","https:\/\/x.com\/capital10x","https:\/\/www.instagram.com\/capital10x","https:\/\/www.linkedin.com\/company\/capital10x\/","https:\/\/www.pinterest.com\/capital10x","https:\/\/www.youtube.com\/Capital10X\/"]},{"@type":"Person","@id":"https:\/\/capital10x.com\/old\/#\/schema\/person\/75fddffbd75d63e9226bc4c592e9a851","name":"Duane Hope","image":{"@type":"ImageObject","inLanguage":"en-CA","@id":"https:\/\/capital10x.com\/old\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1e094aea10a79b65e157d5f0d9968719f11d1fafb952b910a18796349f2e38e9?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1e094aea10a79b65e157d5f0d9968719f11d1fafb952b910a18796349f2e38e9?s=96&d=mm&r=g","caption":"Duane Hope"},"description":"Duane Hope is a Partner at Capital 10X, he brings over 15 years of communications and research experience to the firm. His research and writing has appeared in publications for North American, European and Asian audiences.","sameAs":["http:\/\/capital10x.com"],"url":"https:\/\/capital10x.com\/old\/author\/duanehope\/"}]}},"_links":{"self":[{"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/posts\/27158","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/users\/25"}],"replies":[{"embeddable":true,"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/comments?post=27158"}],"version-history":[{"count":1,"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/posts\/27158\/revisions"}],"predecessor-version":[{"id":27159,"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/posts\/27158\/revisions\/27159"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/media\/27154"}],"wp:attachment":[{"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/media?parent=27158"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/categories?post=27158"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/tags?post=27158"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}